If party season in the Square Mile looks set to be a washout again this year, at least its inhabitants of bankers, lawyers and accountants have plenty of work to occupy them in the coming few weeks with a slew of late IPOs ready to go live.
Normally, December is a quiet period for new listings. Not so this time around.
Sister companies Open Orphan and Poolbeg, both chaired by serial entrepreneur Cathal Freil, also had a decent week. The latter announced it was moving into oral vaccines in a tie-up with a microencapsulation specialist, resulting in a 16 per cent share price jump.
Meanwhile, there was a flurry of follow-on buying after last Friday’s news that Open Orphan had landed a £10million contract to carry out an influenza human challenge study. The shares ended the week 14 per cent better off.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
